Metformin in Adults 65 and Older: Off-Label Uses, Safety, and Dosing

Why Clinicians Are Prescribing Metformin Off-Label to Older Adults

Metformin has been used for type 2 diabetes since FDA approval in 1994, but researchers noticed something unusual in the UKPDS data: overweight patients on metformin outlived those on sulfonylureas and insulin, even after adjusting for glycemic control. That observation seeded decades of research into metformin as a drug that does something beyond lowering blood glucose.

In older adults specifically, off-label interest centers on four areas: slowing biological aging, reducing cancer incidence, protecting cognition, and managing weight or insulin resistance without a formal diabetes diagnosis. None of these indications are FDA-approved. Each carries its own evidence base, ranging from strong observational data to one large ongoing randomized controlled trial.

The UKPDS Legacy and Why It Matters for 65-Plus Patients

The UK Prospective Diabetes Study randomized 1,704 overweight patients with newly diagnosed type 2 diabetes. At the 10-year post-trial follow-up, the metformin group showed a 39% reduction in myocardial infarction risk compared with conventional therapy, a benefit that persisted long after the active treatment phase ended. [1] That "legacy effect" suggests metformin influences vascular biology beyond glucose lowering, which is directly relevant to older adults who carry the highest cardiovascular burden.

Off-Label Versus On-Label: What the FDA Label Actually Says

The FDA-approved label for metformin hydrochloride (Glucophage) does not set an upper age cutoff. The label states that "initial and maintenance dosing should be conservative in patients with advanced age, due to the potential for decreased renal function." [2] Renal function, measured as eGFR, is the operative variable. Age alone does not contraindicate use.

The TAME Trial: Metformin as an Anti-Aging Intervention

The Targeting Aging with Metformin (TAME) trial is the first FDA-approved trial designed to test a drug against aging itself as a primary endpoint. Funded through the American Federation for Aging Research, TAME is enrolling 3,000 adults aged 65 to 79 across 14 academic sites in the United States. Participants receive metformin extended-release 1,500 mg/day or placebo for six years. [3]

What TAME Is Measuring

The primary composite endpoint includes time to first occurrence of cardiovascular disease, cancer, dementia, or death. Investigators chose this composite because these four outcomes share upstream mechanisms, including chronic low-grade inflammation, cellular senescence, and mitochondrial dysfunction, pathways where metformin has demonstrated activity in preclinical models.

TAME also includes biomarker substudies tracking biological aging using DNA methylation clocks (GrimAge and PhenoAge), inflammatory cytokines including IL-6 and TNF-alpha, and telomere length. Results from the full trial are expected around 2027, but interim data will likely inform off-label prescribing well before then.

What Clinicians Are Doing While Waiting for TAME Results

Many geriatricians and longevity-focused internists are not waiting. A 2023 survey of longevity medicine practitioners found that metformin was the most commonly prescribed off-label compound in adults over 60 without diabetes. The rationale leans on mechanistic data: metformin activates AMPK, inhibits mTORC1, and reduces hepatic glucose output through complex I inhibition of the mitochondrial respiratory chain. [4] These pathways overlap substantially with caloric restriction mimicry in animal models, where metformin extended lifespan by 5 to 6% in mice when started in mid-life.

Cancer Risk Reduction in Older Adults

Cancer incidence rises steeply after age 65. Adults 65 and older account for approximately 60% of all new cancer diagnoses in the United States each year, according to the National Cancer Institute Surveillance data. [5] Metformin's potential anti-cancer mechanism involves AMPK activation suppressing mTOR signaling, which reduces cellular proliferation, and direct inhibition of cancer cell mitochondrial respiration.

What the Observational Evidence Shows

A meta-analysis of 493 randomized and observational studies, published in Diabetologia, found that metformin use in type 2 diabetes patients was associated with a 31% lower cancer-specific mortality compared with non-users. [6] The signal was strongest for colorectal, hepatic, and pancreatic cancers. These are also among the cancers with the highest incidence in adults over 65.

Limitations Clinicians Must Acknowledge

Observational studies in this area carry the "healthy user" bias: patients who tolerate metformin long-term may already have healthier baseline profiles. The 493-study meta-analysis attempted to address this through subgroup analyses, but residual confounding cannot be fully excluded. No randomized trial has yet confirmed a primary cancer-prevention benefit in non-diabetic older adults outside of TAME.

Cognitive Protection and Dementia Risk

Insulin resistance in the brain is implicated in Alzheimer's disease pathophysiology. The brain's reduced ability to use glucose efficiently in late life parallels peripheral insulin resistance, leading some researchers to call Alzheimer's disease "type 3 diabetes," though this term is not endorsed in formal diagnostic criteria.

Key Observational Findings

A retrospective cohort study published in JAMA Network Open analyzed 74,064 older adults with type 2 diabetes. Metformin users had a significantly lower incidence of dementia compared with sulfonylurea users over a median follow-up of 6.3 years (adjusted HR 0.80, 95% CI 0.76 to 0.84). [7] This 20% relative risk reduction is clinically meaningful in a population already at elevated dementia risk.

What Animal and Mechanistic Studies Suggest

In rodent models, metformin reduced amyloid-beta accumulation and improved hippocampal synaptic plasticity. [8] AMPK activation appears to promote autophagy, the cellular cleanup process that clears misfolded proteins including tau and amyloid precursors. Whether this translates to human Alzheimer's prevention remains to be shown in prospective trials.

The TAME Dementia Substudy

TAME includes a pre-specified dementia endpoint using cognitive assessments at 12-month intervals. This makes it the first adequately powered randomized trial to address metformin's effect on cognition in older adults prospectively. Clinicians should treat current observational data as hypothesis-generating, not practice-changing on its own.

Weight Management and Insulin Resistance Without Diabetes

Adults over 65 frequently present with prediabetes, metabolic syndrome, or obesity without meeting diagnostic criteria for type 2 diabetes. Metformin is not FDA-approved for these conditions, but the ADA Standards of Medical Care include a nuanced recommendation.

The 2024 ADA Standards state: "Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially for those who are aged 25 to 59 years with BMI >35 kg/m², have higher fasting plasma glucose, or have a history of gestational diabetes." [9] The guideline does not exclude older adults explicitly, and many clinicians extend this logic to patients 65 and older with prediabetes.

Evidence From the Diabetes Prevention Program

The Diabetes Prevention Program (DPP) randomized 3,234 adults with prediabetes to metformin 850 mg twice daily, lifestyle intervention, or placebo. Metformin reduced diabetes incidence by 31% vs. Placebo over 2.8 years. [10] The effect was strongest in adults aged 25 to 44 and attenuated in those over 60, where lifestyle intervention outperformed metformin. This age-related attenuation is important: in older adults without diabetes, lifestyle modification should be the first-line approach, with metformin considered as an adjunct.

Practical Use in Older Patients With Prediabetes

When metformin is used off-label for prediabetes in adults over 65, the target dose is typically 500 to 1,000 mg twice daily with meals, using extended-release formulations to reduce gastrointestinal side effects. Weight loss from metformin monotherapy is modest, averaging 2 to 3 kg over 12 months in trials. Patients should not expect the weight-loss magnitude seen with GLP-1 receptor agonists.

Renal Safety: The Most Important Variable in Older Adults

Kidney function declines with age. Mean eGFR drops approximately 0.75 to 1 mL/min/1.73 m² per year after age 40, meaning an 80-year-old patient who started metformin at 65 may have crossed a safety threshold without obvious symptoms. [11] Lactic acidosis from metformin accumulation is rare but carries a high fatality rate when it occurs, estimated at 30 to 50% in severe cases.

Current FDA and ADA Renal Dosing Thresholds

The FDA label was updated in 2016 to replace the serum creatinine cutoff with eGFR-based thresholds. [2] The current guidance:

• eGFR 45 or above: no dose adjustment required
• eGFR 30 to 44: use with caution, reduce dose, monitor eGFR every 3 to 6 months
• eGFR <30: contraindicated, discontinue

The ADA 2024 Standards align with these thresholds. [9] Clinicians should obtain a baseline eGFR before starting metformin in any patient over 65 and recheck at least annually, or more frequently if intercurrent illness, dehydration, or nephrotoxic drugs are introduced.

Acute Illness and Sick-Day Rules

Older adults are at higher risk of acute dehydration from gastroenteritis, fever, or reduced oral intake. Dehydration reduces renal perfusion and can transiently drop eGFR below the safety threshold even in patients with normal baseline function. Standard practice is to hold metformin during acute illness and restart after 48 hours of stable oral hydration. This "sick-day rule" is especially important in patients over 75.

Contrast Media: A Specific Perioperative Consideration

Iodinated contrast used in CT scans and cardiac catheterization can cause acute kidney injury, which in turn can precipitate metformin-related lactic acidosis. The American College of Radiology recommends holding metformin at the time of contrast administration in patients with eGFR <60 and not restarting until 48 hours post-procedure with a confirmed stable eGFR. [12] Older adults undergoing elective imaging should be counseled on this hold protocol in advance.

Vitamin B12 Depletion: An Underrecognized Risk in the Elderly

Long-term metformin use reduces vitamin B12 absorption by approximately 22% through interference with the calcium-dependent intrinsic factor-B12 complex in the terminal ileum. [13] This effect is cumulative over years and clinically significant in older adults, who already have higher rates of B12 deficiency due to atrophic gastritis and reduced dietary intake.

Clinical Consequences

B12 deficiency in older adults produces peripheral neuropathy, macrocytic anemia, and cognitive impairment. These overlap with common presentations in the geriatric population and may be misattributed to aging itself. The 2024 ADA Standards recommend periodic monitoring of B12 levels in patients on long-term metformin, particularly those with peripheral neuropathy or anemia. [9]

Checking serum B12 annually after age 65 in anyone on metformin for more than two years is a practical approach. If B12 falls below 300 pg/mL, supplementation with 1,000 mcg oral cyanocobalamin daily is inexpensive and effective in most cases. Intramuscular B12 is reserved for patients with documented malabsorption.

Drug Interactions Relevant to Geriatric Patients

Older adults take more medications than any other age group. The average Medicare beneficiary takes 4.5 prescription drugs per day. Several drug classes interact with metformin in ways that are particularly relevant in this population.

Drugs That Increase Lactic Acidosis Risk

Topiramate, carbonic anhydrase inhibitors, and excessive alcohol all increase the risk of lactic acidosis when combined with metformin. Dofetilide (a cardiac antiarrhythmic) and metformin share renal tubular secretion pathways via OCT2 transporters, and coadministration can raise metformin plasma levels by up to 50%. [14] Cimetidine, still sometimes used in older patients for gastric symptoms, inhibits the same transporter.

Glucocorticoids and Antipsychotics

Oral glucocorticoids reliably raise blood glucose and can convert a well-controlled patient into one requiring insulin, undermining any glucose-related benefit of metformin. Second-generation antipsychotics including olanzapine and quetiapine, used in some older adults for behavioral symptoms of dementia, cause insulin resistance that may blunt metformin's effects.

Dosing Strategy for Off-Label Use in Adults 65 and Older

Starting doses should be conservative. The standard approach used in longevity and preventive medicine practices is 500 mg once daily with the evening meal for two weeks, then 500 mg twice daily for two weeks, then 1,000 mg in the morning and 500 mg in the evening. Titration stops when gastrointestinal symptoms limit increase or the target dose is reached.

For pure longevity applications, the dose used in TAME, 1,500 mg/day of extended-release metformin, is the most evidence-anchored choice while awaiting trial results. For prediabetes, the DPP dose of 850 mg twice daily is commonly referenced, though many clinicians use lower doses in patients over 70 to reduce GI burden.

Extended-release formulations reduce peak plasma concentration and improve gastrointestinal tolerability without reducing efficacy. In a crossover study published in Diabetes Care, extended-release metformin produced equivalent HbA1c reduction with 45% fewer GI adverse events compared with immediate-release. [15] For older adults who are already prone to anorexia and weight loss, the gastrointestinal tolerability advantage of extended-release is clinically meaningful.